plate vii - the publisher
About Legal TB-500.
What this project is, what the word 'legal' in the name does and does not mean, and the line we hold around the science.
What this site is
Legal TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the public regulatory record.
The organizing idea is a single, stubborn distinction: TB-500 is a seven-residue synthetic fragment, while almost all of its efficacy literature is on the full-length 43-residue protein [5]. We treat that gap as the central fact, not a disclaimer buried at the bottom. Every quantitative claim on this site is tied to a numbered source on the references page, and where a study used the full protein rather than the fragment, we say so.
What 'Legal' in the name means
The word 'legal' in this site's name is editorial framing — it signals that the site reads the legal and regulatory record carefully, with the FDA 503A status and the WADA standing placed up front. It is not a claim that TB-500 is approved, and it is not legal advice. TB-500 is not an FDA-approved drug, and FDA placed it in 503A Category 2 in its September 29, 2023 update [18].
We describe the lawful compounding pathway in general terms and we cite the FDA pages that establish the current status. We do not name pharmacies, clinics, telehealth providers, or vendors; we do not provide dosing; and we do not describe ways to obtain any substance outside the lawful framework. The honest reading of the record — including its safety signal and its human-data gaps — is the entire point of the project.
How we handle the science
We lead with what was measured and attribute it afterward. We prefer a precise blank — 'there is no validated human pharmacokinetic half-life for the fragment' — to a vague reassurance [6]. We surface the misses as plainly as the hits: the non-monotonic stroke dose-response [4], the null muscle-strength result in mdx mice [5], and the porcine ischemia-reperfusion study where systemic Tβ4 did not help [5]. The tumor and angiogenesis safety signal is stated as a recognized concern wherever it is relevant [5]. The aim is a calm, checkable record — not a verdict, and not a sales pitch.